You are here: Industry Insights > NeuroVive

News List

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study prnasia
December 25, 2019
The first part of the study, in which the effect of food intake on the uptake of KL1333 after a single dose had been assessed in healthy volunteers, showed promising drug properties and safety data. In the second part of the study, five cohorts of healthy
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation prnasia
August 06, 2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to ...
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study prnasia
July 05, 2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333 ...
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report en-cphi.cn
March 27, 2019
NeuroVive Pharmaceutical AB today announced that the English version of the Annual report for 2018 is now available on the company's website.
NeuroVive Receives KL1333 Clinical Trial Regulatory Approval americanpharmaceuticalreview
October 12, 2018
NeuroVive Pharmaceutical has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA).
NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project prnasia
January 30, 2018
NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondrial myopathy
European Commission grants orphan drug designation to NeuroVive KL pharmaasia
December 22, 2017
The NeuroVive KL1333 programme targets oral treatment of Mitochondrial Myopathy, Encephalopathy, Lactic acidosis and Stroke-like episodes (MELA
NeuroVive and Yungjin Pharm start clinical development pharmaasia
July 13, 2017
NeuroVive and Yungjin Pharm starts clinical development in Genetic Mitochondrial disease.
NeuroVive and Yungjin Pharm start clinical development pharmaasia
July 13, 2017
NeuroVive and Yungjin Pharm starts clinical development in Genetic Mitochondrial disease.
NeuroVive receives research grant from Vinnova pharmaasia
June 07, 2017
NeuroVive Pharmaceutical AB announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseases.

Previous page 1 2 Next page